Novel fusion protein drug for Alzheimer's disease circumvents the neurotoxic inflammatory side effects
Although Aduhelm, a monoclonal antibody targeting amyloid beta (Aβ), recently became the first US FDA approved drug for Alzheimer's disease (AD) based on its ability to decrease Aβ plaque burden in AD patients, its effect on cognitive improvement is still controversial.
Source: news-medical.net